Class summary at a glance.

Every drug in the Antiemetic class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $38.7Mcombined across class
Total Rx claims: 4.6M2.3M unique beneficiaries
Generic mfrs (active): 9across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Meclizine

Brand: MECLIZINE HYDROCHLORIDE · 4.6M Part D claims (CY24) · 2.3M beneficiaries · First FDA approval: 2010-02-12

9 generic mfrs 134 plans require PA

Low NADAC$0.047

→

Avg plan cost$0.179

Part D spend $38.7M 4× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.